Bullish
Johnson & Johnson's RYBREVANT® plus chemotherapy shows longest survival in EGFR-mutated lung cancer
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) combined with chemotherapy has demonstrated the longest reported median overall survival in patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC). This dual-targeting approach, which addresses both EGFR and MET pathways, offers a significant advancement for a patient population with historically poor outcomes.
Key points
- RYBREVANT® plus chemotherapy achieves longest reported survival in EGFR-mutated lung cancer.
Sources
AI-generated from public news sources. Not financial advice.
